The detection rate and variants of monoclonal gammopathy among patients in a multidisciplinary therapeutic hospital
- Authors: Mrykhin N.1, Lysenko L.1, Chebotareva N.1, Rameev V.1, Androsova T.1, Roshchupkina S.1, Gitel E.1, Kogarko I.2, Maryina S.3
-
Affiliations:
- M. Sechenov First Moscow State Medical University (Sechenov University)
- Semenov Institute of Chemical Physics Russian Academy of Sciences
- National Medical Research Center of Flematology
- Issue: Vol 30, No 2 (2019)
- Pages: 54-59
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115172
- DOI: https://doi.org/10.29296/25877305-2019-02-11
- ID: 115172
Cite item
Abstract
Keywords
Full Text
About the authors
N. Mrykhin
M. Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
Moscow
L. Lysenko
M. Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
Professor, MD Moscow
N. Chebotareva
M. Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
Candidate of Medical Sciences Moscow
V. Rameev
M. Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
Candidate of Medical Sciences Moscow
T. Androsova
M. Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
Candidate of Medical Sciences Moscow
S. Roshchupkina
M. Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
MrykhinProfessor L. Lysenko1, MD; N. Chebotareva1, Candidate of Medical Sciences; V.Rameev1, Candidate of Medical Sciences; T. Androsova’, Candidate of Medical Sciences; S. Roshchupkina1 ; £ Git el1. Candidate of Medical Sciences; I. Kogarkos, MD; S. Maryina2 Moscow
E. Gitel
M. Sechenov First Moscow State Medical University (Sechenov University)
Email: natasha_tcheb@mail.ru
Candidate of Medical Sciences Moscow
I. Kogarko
Semenov Institute of Chemical Physics Russian Academy of Sciences
Email: natasha_tcheb@mail.ru
MD Moscow
S. Maryina
National Medical Research Center of Flematology
Email: natasha_tcheb@mail.ru
Moscow
References
- Kyle R., Rajkumar S. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma // Curr. Hematol. Malig. Rep. - 2010; 5 (2): 62-9. doi: 10.1007/si 1899-010-0047-9.
- Zingone A., Kuehl M. Pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and progression to multiple myeloma // Semin Hematol. - 2011 ; 48 (1 ): 4-12. doi: 10.1053/j.seminhematol.2010.11.003.
- Merlini G., Palladini G. Differential diagnosis of monoclonal gam-mopathy of undetermined significance // Hematology. Am. Soc. Hematol. Educ. Program. -2012; 2012: 595-603. doi: 10.1182/asheduca-tion-2012.1.595.
- Knight G., Gao L., Gragnani L. et al. Detection of WA В cells in hepatitis С virus infection: a potential prognostic marker for cryo-globulinemic vasculitis and В cell malignancies // Arthr. Rheum. - 2010; 62: 2152-9. doi: 10.1002/art.27490.
- Gertz M. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management // Am. J. Hematol. - 2011; 86: 181-6. doi: 10.1002/ajh.21934.
- Debiec H., Hanoy M., Francois A. et al. Recurrent membranous nephropathy in an allograft caused by lgG3ic targeting the PLA2 receptor // J. Am. Soc. Nephrol. - 2012; 23 (12): 1949-54. doi: 10.1681/ASN.2012060577.
- Kapoulas S., Raptis V., Papaioannou M. New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies // Nephrol. Ther. - 2015; 11 (3): 135-43. doi: 10.1016/j.nephro.2014.12.005.
- Bridoux F., Leung N., Hutchison C. et al. Diagnosis of monoclonal gammopathy of renal significance // Kidney Int. - 2015; 87 (4): 698-711. doi: 10.1038/ki.2014.408.
- Kyle R., Therneau T., Rajkumar S. et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later // Mayo Clin. Proc. - 2004; 79 (7): 859-66. doi: 10.1016/S0025-6196(11 )62151 -4.
- Landgren 0., Kyle R., Pfeiffer R. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study // Blood. - 2009; 113: 5412-7. doi: 10.1182/blood-2008-12-194241.
- Landgren 0., Graubard B., Katzmann J. et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey // Leukemia. -2014; 28 (7): 1537-42. doi: 10.1038/leu.2014.34.
- Kyle R., Rajkumar S. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression // Br. J. Haematol. - 2007; 139 (5): 730-43. DOI: 10.1111 /j.1365-2141,2007.06873.x.
- Landgren O., Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes // J. Intern. Med. - 2017; 281 (4): 365-82. doi: 10.1111/joim.12590.
- Doyle L., Gundrum J., Farnen J. et al. Determining why and which clinicians order serum protein electrophoresis (SPEP), subsequent diagnoses based on indications, and clinical significance of routine follow-up: a study of patients with monoclonal gammopathy of undetermined significance (MGUS) // Blood. - 2009; 114 (22): 4883.
- Weiss B., Abadie J., Verma P. et al. A monoclonal gammopathy precedes multiple myeloma in most patients // Blood. - 2009; 113: 5418-22. DOI: 10.1182/ blood-2008-12-195008. выставка IPhEB 02-04 апреля 2019 Сан кт- Петербург
- Kyle R. Monoclonal gammopathy of undetermined significance: natural history in 241 cases // Am. J. Med. - 1978; 64: 814-26.
- Go R., Rajkumar S. How I manage monoclonal gammopathy of undetermined significance // Blood. - 2018; 131 (2): 163-73. doi: 10.1182/blood-2017-09-807560.
- Rajkumar S., Kyle R., Therneau T. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance // Blood. - 2005; 106: 812-7. doi: 10.1182/blood-2005-03-1038.
- Bida J., Kyle R., Therneau T. et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients // Mayo Clin. Proc. - 2009; 84 (8): 685-93. doi: 10.1016/S0025-6196(11)60518-1.
- Leung N., Bridoux F., Hutchison C. et al. International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant // Blood. -2012; 120 (22): 4292-5. DOI: 10.1182/ blood-2012-07-445304.
- Sethi S., Fervenza F., Rajkumar S. Spectrum of manifestations of monoclonal gammopathy-associated renal lesions // Curr. Opin. Nephrol. Hypertens. - 2016; 25:127-37. doi: 10.1097/MNH.0000000000000201.
- Steiner N., Göbel G., Suchecki P. et al. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients // Oncotarget. - 2017; 9 (2) : 2344-56. doi: 10.18632/oncotarget.23412.